High concordance of different molecular assays in the determination of HRD associated GIS in high grade epithelial ovarian cancer

Poly(ADP-ribose)-polymerase 1 inhibitors (PARPi) are currently in use in certain clinical settings for patients with ovarian cancer. Patients with homologous recombination repair deficiency (HRD) within their tumor which was defined as present if BRCA was mutated (BRCAm) and/or HRD-associated genomic instability (GIS) scores were high, revealed higher benefits, demonstrating the value of biomarker testing in this context. Currently the Myriad MyChoice assay is the most commonly used assay for HRD detection in clinical studies but other molecular assays can also be applied.